Healthcare
Fate Therapeutics, Inc.(FATE)
Live Price
Offline$2.09
+6.63% today
1Y Change
+80.17%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $270.00M
- Revenue Growth
- -51.2%
- EPS Growth
- +29.9%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Fate Therapeutics, Inc. (FATE) is a Healthcare stock with a market cap of $270.00M and listed on NASDAQ. The stock last traded around $2.09 and up 80.2% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -51.2%, EPS growth of +29.9%, a dividend yield of 0.0%. What stands out right now is revenue -51.2%, EPS +29.9%, free cash flow +9.4% with operating margin -2222.4% and ROIC -51.4%. Valuation already assumes a fairly strong business story at price/sales 40.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines FATE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-51.2% vs +7.6% peer median
Operating Margin
Below sector median
-2222.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -51.2% and EPS is at +29.9%, with operating margin around -2222.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | -4.9% | -16.0% | -16.9% |
2026 Feb 26, 2026 | +0.0% | -5.1% | -11.5% | -21.2% |
2025 Nov 13, 2025 | +6.9% | -3.0% | +1.0% | +16.2% |
Benchmark Edge
FATE vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
FATE
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
FATE Max Drawdown
-41.82%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for FATE and SPY.
Company Overview
Fate Therapeutics, Inc.
NASDAQ Global Market
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
- Leadership
- Bahram Valamehr
- IPO Date
- Oct 1, 2013
- Employees
- 181
- Street Address
- 12278 Scripps Summit Drive
- Mailing
- San Diego, CA, 92131
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 875 1800
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 40.1
- Price/Book
- 1.3
Growth
- Revenue
- -51.2%
- EPS
- +29.9%
- Free Cash Flow
- +9.4%
Profitability
- Gross Margin
- -94.1%
- Operating Margin
- -2222.4%
- Net Margin
- -2051.1%
- ROE
- -55.0%
- ROIC
- -51.4%
Balance Sheet
- Debt/Equity
- 0.38
- Current Ratio
- 5.79
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.